Adipose Macrophage sEVs in MASH: Promise With Mechanistic Gaps- Gastroenterology Feb.26

Introduction

Metabolically–dysfunction–associated steatohepatitis (MASH) is increasingly recognised as a multiorgan disease, with pathogenic signalling extending beyond the liver. Rohm et al. propose an intriguing extrahepatic mechanism: adipose tissue macrophage (ATM)–derived small extracellular vesicles (sEVs) carrying fibrogenic microRNAs (miR-155 and miR-34a) that activate hepatic stellate cells and promote liver fibrosis.

This commentary welcomes the concept—but highlights important mechanistic and translational gaps that must be addressed before this pathway can be safely targeted in humans.

Why this work matters

Current antifibrotic strategies in MASH have largely focused on intrahepatic pathways. Demonstrating that adipose–liver communication via sEVs contributes to fibrosis would:

expand therapeutic targets beyond the liver,

explain why fibrosis can progress despite hepatic metabolic improvements,

and open the door to novel interventions targeting immune–metabolic crosstalk.

Key concerns and unresolved questions

1️⃣ Which macrophages are actually responsible?

The study identifies expansion of CD9⁺ Trem2⁺ lipid-associated macrophages in adipose tissue. However:

it does not distinguish resident ATMs from monocyte-derived infiltrating macrophages,

nor does it clarify which subset produces fibrogenic sEVs.

Why this matters clinically:

Targeting “ATMs” broadly could disrupt beneficial immune or metabolic functions. Defining the exact macrophage subset is essential for selective and safer therapeutic strategies.

2️⃣ Why are miR-155 and miR-34a enriched in sEVs?

The proposed mechanism assumes these miRNAs are selectively packaged into sEVs, but it remains unclear whether:

they are simply overexpressed in donor macrophages, or

actively sorted into vesicles via RNA-binding proteins.

Why this matters:

If miRNA enrichment is an active sorting process, it may be pharmacologically targetable. If passive, targeting upstream macrophage activation may be more effective than targeting sEVs themselves.

3️⃣ Is miRNA inhibition safe and durable?

In vitro, antagomirs against miR-155 and miR-34a block stellate cell activation. However:

miR-155 plays critical roles in immune regulation,

miR-34a is involved in senescence and tumor suppression.

Clinical concern:

Systemic or long-term inhibition could lead to immunosuppression or oncogenic risk. Transient in vitro benefit does not guarantee sustained fibrosis regression or safety in vivo.

4️⃣ Macrophages are not static—how does polarisation matter?

ATMs exist along a dynamic phenotypic spectrum, not fixed “pro-fibrotic” states. Changes in metabolic or inflammatory cues could:

alter macrophage polarisation,

reshape sEV cargo,

and modify downstream fibrogenic signalling.

Why this matters:

Therapeutic strategies must account for macrophage plasticity, or risk short-lived or context-dependent efficacy.

Translational interpretation

This work represents an important conceptual advance—highlighting adipose tissue as an active driver of liver fibrosis in MASH via extracellular vesicles. However, before ATM-sEVs can be considered viable therapeutic targets, we need:

clearer macrophage lineage tracing,

mechanistic validation of miRNA sorting,

long-term in vivo safety and efficacy data, and

strategies that preserve beneficial immune–metabolic functions.

Bottom-line takeaway for GastroAGI

ATM-derived sEVs offer a compelling explanation for extrahepatic drivers of fibrosis in MASH—but therapeutic translation will require far more mechanistic precision and safety validation.

One-line GastroAGI takeaway

Adipose–liver communication via macrophage sEVs is a promising—but still incomplete—therapeutic frontier in MASH.